Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
125I seed implantation combined with camrelizumab for solid tumors after radiotherapy and chemotherapy failure
ChiCTR2100052147Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in Nonhematologic neoplasms, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Objective response rate, Disease control rate and 1 more. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2100052147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052147.